These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21484140)

  • 21. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
    Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study.
    Wu X; Zhou J; Xie W; Ding H; Ou X; Chen G; Ma A; Xu X; Ma H; Xu Y; Liu X; Meng T; Wang L; Sun Y; Wang B; Kong Y; Ma H; You H; Jia J
    Infect Drug Resist; 2019; 12():745-757. PubMed ID: 31015765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.
    Ha M; Zhang G; Diao S; Lin M; Wu J; Sun L; She H; Shen L; Huang C; Shen W; Huang Z
    Intern Med; 2012; 51(12):1509-15. PubMed ID: 22728482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B.
    Chu M; Cho SM; Choe BH; Cho MH; Kwon S; Lee WK
    J Pediatr Gastroenterol Nutr; 2012 Dec; 55(6):648-52. PubMed ID: 22688509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LAM add-on ADV combination therapy or ETV monotherapy for CHB patients with suboptimal response to ADV.
    Jia H; Ding F; Chen J; Zhang Y; Xiang D; Lian J; Zeng L; Yu L; Hu J; Li Y; Lu Y; Liu Y; Zheng L; Li L; Yang Y
    Ann Hepatol; 2015; 14(2):175-80. PubMed ID: 25671826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of 3 years of adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance.
    Song MN; Hong MZ; Luo DQ; Huang WQ; Min F; Fan RH; Wu WB; Zhang L
    World J Hepatol; 2012 Dec; 4(12):389-93. PubMed ID: 23355917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir.
    Son CY; Ryu HJ; Lee JM; Ahn SH; Kim DY; Lee MH; Han KH; Chon CY; Park JY
    Liver Int; 2012 Aug; 32(7):1179-85. PubMed ID: 22452737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switching Lamivudine with Adefovir Dipivoxil Combination Therapy to Entecavir Monotherapy Provides Better Viral Suppression and Kidney Safety.
    Lian JS; Zhang XL; Lu YF; Chen JY; Zhang YM; Jia HY; Zhang Z; Yang YD
    Int J Med Sci; 2019; 16(1):17-22. PubMed ID: 30662324
    [No Abstract]   [Full Text] [Related]  

  • 29. Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B.
    Kurashige N; Hiramatsu N; Ohkawa K; Yakushijin T; Kiso S; Kanto T; Takehara T; Kasahara A; Doi Y; Yamada A; Oshita M; Mita E; Hagiwara H; Nagase T; Yoshihara H; Hayashi E; Imai Y; Kato M; Kashihara T; Hayashi N
    J Gastroenterol; 2009; 44(6):601-7. PubMed ID: 19387534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels.
    Shi H; Han Z; Liu J; Xue J; Zhang S; Zhu Z; Xia J; Huang M
    Med Sci Monit; 2017 Nov; 23():5230-5236. PubMed ID: 29095799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy.
    Wang LC; Chen EQ; Cao J; Liu L; Wang JR; Lei BJ; Tang H
    J Viral Hepat; 2010 Mar; 17(3):178-84. PubMed ID: 19656287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective study: Adefovir versus Entercavir for Chronic Hepatitis B.
    Chen EQ; Zhou TY; Liu L; Liu C; Lei M; Tang H
    Hepat Mon; 2011 Jan; 11(1):27-31. PubMed ID: 22087113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.
    Lee KS; Kweon YO; Um SH; Kim BH; Lim YS; Paik SW; Heo J; Lee HJ; Kim DJ; Kim TH; Lee YS; Byun KS; Kim D; Lee MS; Yu K; Suh DJ
    Clin Mol Hepatol; 2017 Dec; 23(4):331-339. PubMed ID: 28946736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies.
    Kim HS; Yim HJ; Jang MK; Park JW; Suh SJ; Seo YS; Kim JH; Kim BH; Park SJ; Lee SH; Kim SG; Kim YS; Lee JI; Lee JW; Kim IH; Kim TY; Kim JW; Jeong SH; Jung YK; Park H; Hwang SG;
    World J Gastroenterol; 2015 Oct; 21(38):10874-82. PubMed ID: 26478678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy.
    Wang ML; Chen EQ; Zhang DM; Du LY; Yan LB; Zhou TY; Lei XZ; Lei BJ; Lu JJ; Liao J; Tang H
    J Viral Hepat; 2017 Nov; 24 Suppl 1():21-28. PubMed ID: 29082645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients.
    Chen CH; Hu TH; Hung CH; Lu SN; Wang JH; Chang MH; Changchien CS; Lee CM
    Hepatol Int; 2013 Jul; 7(3):832-43. PubMed ID: 26201920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
    Ryu HJ; Lee JM; Ahn SH; Kim DY; Lee MH; Han KH; Chon CY; Park JY
    J Med Virol; 2010 Nov; 82(11):1835-42. PubMed ID: 20872709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
    Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.